Eyebright Medical Technology (Beijing) Co., Ltd. (SHA:688050)
China · Delayed Price · Currency is CNY 42.38
-0.72 (-1.67%)
May 28, 2026, 3:00 PM CST
SHA:688050 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,515 | 1,474 | 1,404 | 947.42 | 575.86 | 431.2 |
Other Revenue | 8.38 | 8.38 | 6.4 | 3.75 | 3.64 | 1.87 |
| 1,524 | 1,483 | 1,410 | 951.18 | 579.5 | 433.07 | |
Revenue Growth (YoY) | 4.60% | 5.16% | 48.24% | 64.14% | 33.81% | 58.61% |
Cost of Revenue | 583.51 | 556.55 | 479.83 | 230.04 | 88.35 | 68.08 |
Gross Profit | 940.25 | 926.15 | 930.19 | 721.14 | 491.15 | 364.99 |
Selling, General & Admin | 459.14 | 448.26 | 370.67 | 296.94 | 178.57 | 142.27 |
Research & Development | 87.06 | 94.67 | 106.42 | 91.95 | 63.9 | 51.91 |
Other Operating Expenses | 16.35 | 8.55 | 4.75 | 14.98 | 8.69 | 7.17 |
Operating Expenses | 577.82 | 561.22 | 492.69 | 412.99 | 259.52 | 207.1 |
Operating Income | 362.43 | 364.93 | 437.5 | 308.16 | 231.62 | 157.89 |
Interest Expense | -21.94 | -22.98 | -20.73 | -9.81 | -2.02 | -0.74 |
Interest & Investment Income | 7.82 | 7.68 | 4.17 | 19.98 | 21.97 | 25.56 |
Currency Exchange Gain (Loss) | 0.8 | 0.8 | -0.46 | 0.62 | -0.23 | -0.92 |
Other Non Operating Income (Expenses) | -3.83 | -1.69 | -2.08 | 0.03 | -0.52 | -0.15 |
EBT Excluding Unusual Items | 345.27 | 348.73 | 418.39 | 318.97 | 250.81 | 181.65 |
Impairment of Goodwill | -57.36 | -57.36 | - | - | - | - |
Gain (Loss) on Sale of Investments | -0.66 | 0.2 | -0.69 | -1.84 | 1.49 | 0.2 |
Gain (Loss) on Sale of Assets | -0.03 | -0.09 | -0.08 | 0.11 | 0.01 | 0.02 |
Asset Writedown | -13.6 | -14.8 | -1.98 | - | - | - |
Other Unusual Items | 13.22 | 12.58 | 15.45 | 10.43 | 11.77 | 5.9 |
Pretax Income | 286.84 | 289.26 | 431.1 | 327.67 | 264.08 | 187.77 |
Income Tax Expense | 50.25 | 48.67 | 44.02 | 41.62 | 36.85 | 20.01 |
Earnings From Continuing Operations | 236.59 | 240.59 | 387.08 | 286.05 | 227.23 | 167.75 |
Minority Interest in Earnings | 28.3 | 27.58 | 1.32 | 17.93 | 5.46 | 3.59 |
Net Income | 264.89 | 268.17 | 388.4 | 303.98 | 232.69 | 171.34 |
Net Income to Common | 264.89 | 268.17 | 388.4 | 303.98 | 232.69 | 171.34 |
Net Income Growth | -29.93% | -30.96% | 27.77% | 30.63% | 35.80% | 77.45% |
Shares Outstanding (Basic) | 193 | 192 | 189 | 189 | 190 | 189 |
Shares Outstanding (Diluted) | 193 | 192 | 189 | 190 | 190 | 189 |
Shares Change (YoY) | 2.01% | 1.10% | -0.27% | 0.25% | 0.17% | 17.57% |
EPS (Basic) | 1.37 | 1.40 | 2.05 | 1.61 | 1.23 | 0.91 |
EPS (Diluted) | 1.37 | 1.40 | 2.05 | 1.60 | 1.23 | 0.91 |
EPS Growth | -31.31% | -31.71% | 28.13% | 30.31% | 35.58% | 50.93% |
Free Cash Flow | 214.39 | 246.01 | 18.27 | -157.72 | -20.9 | -91.92 |
Free Cash Flow Per Share | 1.11 | 1.28 | 0.10 | -0.83 | -0.11 | -0.49 |
Dividend Per Share | 0.320 | 0.320 | 0.350 | 0.272 | 0.283 | 0.206 |
Dividend Growth | -8.57% | -8.57% | 28.58% | -3.92% | 37.79% | 32.13% |
Gross Margin | 61.71% | 62.46% | 65.97% | 75.82% | 84.75% | 84.28% |
Operating Margin | 23.79% | 24.61% | 31.03% | 32.40% | 39.97% | 36.46% |
Profit Margin | 17.38% | 18.09% | 27.55% | 31.96% | 40.15% | 39.56% |
Free Cash Flow Margin | 14.07% | 16.59% | 1.30% | -16.58% | -3.61% | -21.22% |
EBITDA | 529.68 | 524.42 | 565.96 | 380.52 | 271.42 | 188.07 |
EBITDA Margin | 34.76% | 35.37% | 40.14% | 40.01% | 46.84% | 43.43% |
D&A For EBITDA | 167.25 | 159.49 | 128.46 | 72.36 | 39.79 | 30.18 |
EBIT | 362.43 | 364.93 | 437.5 | 308.16 | 231.62 | 157.89 |
EBIT Margin | 23.79% | 24.61% | 31.03% | 32.40% | 39.97% | 36.46% |
Effective Tax Rate | 17.52% | 16.83% | 10.21% | 12.70% | 13.95% | 10.66% |
Revenue as Reported | 1,524 | 1,483 | 1,410 | 951.18 | 579.5 | 433.07 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.